

WYDUR Board Meeting Minutes
Thursday July 28, 2005
Laramie, WY
Hampton Inn

Members present: Kevin Robinett, Kurt Hopfensperger, Scott Johnston, George Zaharas, Steve Brown, Aimee Lewis, Richard Johnson, Becky Drnas, Kendra Grande, Linda Martin, Dean Wunsch, Bill Keenan, Mike Carpenter, Bill Harrison, and Debra Devereaux

Guests: Tonja Woods, Jill Van Cleave, Angela Fornstrom, John Vandell, Larry Bridger (Pfizer), Terri Craig (Pfizer), Paul Pereira (TAP), Betty Iverson (Wyeth), Kelly Steiner (Merck), and Joan Solem (Lilly)

Introductions and Announcements

- WYDUR Board welcomes two new members: Dr. Kevin Robinett and Dr. Kurt Hopfensperger. All the members of the WYDUR Board were present.
- The minutes of the May 26, 2005 meeting were approved as presented.
- Scott Johnston and Bill Harrison were nominated for Chair of the WYDUR Board. Dr. Harrison was elected as Chair.

Department of Health Report

- Pallindone was taken off the market due to deaths from concurrent alcohol consumption.
- The Board discussed the proposed Zofran criteria. Of 90 cases, 60% of usage was for an unknown diagnosis or a general pregnancy diagnosis, 26% of utilization was for hyperemesis, 13 cases for cancer, and 30 cases as first line therapy in pregnant patients. The Board voted to approve the draft criteria pending final approval after provider feedback is received.
- The draft criteria for overactive bladder agents was discussed. Over 65 yo patients are exempt and the Board decided to change the 14 day trial and failure of a preferred agent to 30 days. The draft criteria will be sent to urologists and 50 randomly selected primary care physicians.
- All erectile dysfunction drugs are quantity limited to 6/month. There will be a new indication for pulmonary hypertension. All prescriptions are subject to prior authorization after review of the sex offender registry.
- The Board discussed Lunesta. Lunesta's t_{1/2} is 6 hours. Current utilization is 114 prescriptions and 83 unique patients at a cost of about \$10,000. The Board approved adding a hard edit for a 3 mg daily doses – no prior authorization. Lunesta utilization will be reviewed in January 2006. The Board requested long term study information from the other companies with hypnotic products. The Board requested that the Lunesta 6 month study be forwarded to them for review.
- The Department of Health will probably provide wrap around coverage for benzodiazepines and barbiturates for the dual eligible pt. switching to Medicare drug coverage 1/1/06.
- PA Statistics – See attached.

Utilization Reviews

- Actiq – Scott Johnston reviewed current utilization. There are twenty patients – 5 with cancer diagnosis and 15 with non-cancer diagnosis. It is indicated for breakthrough pain in cancer and sickle cell anemia. Scott will draft an educational letter to the providers prescribing Actiq.
- The target date for the newly contracted "smart PA" system from ACS is October 1, 2005
- Oxycontin use in worker's comp patients – See attached.
- The Gabitril risk of seizures letters was sent to 3 pain management specialists, 1 ANP, and 57 prescribers. The Board also requested that the letter be sent to all PAs and ANPs.
- There will also be an education letter portion of the web site where all the educational letters will be posted.

Newsletter

- We are still pursuing accreditation for CME and haven't heard from Wyoming Medical Society regarding their ability to partner with WYDUR. The Family Practice Center in Cheyenne is also a possibility.
- Other topics: Atypical antipsychotic and increased mortality in nursing home patients, increased incident of bleeding with concurrent use of SSRIs and NSAIDs.

HID Criteria

- All approved. #2 Promethazine contraindication in < 2 yo pt. will be added to POS hard edits.

Alert Changes

- Keep increase in glucose from niacin (niaspan is less), tramadol and opiates (2 different prescriber).
- Kendra will review thyroid and cardiac glycoside interaction for September meeting.

There being no further business the meeting was adjourned at 3:00 pm.

Respectfully Submitted,

Debra Devereaux, MBA, RPh
WYDUR Manager